Clinical Pharmacokinetics

, Volume 46, Issue 3, pp 209–219

Pharmacokinetics and Therapeutic Drug Monitoring of Newer Antiepileptic Drugs During Pregnancy and the Puerperium

Review Article


The treatment of epilepsy in pregnancy is particularly challenging in that the fetal and maternal risks associated with maternal seizures need to be balanced against the potential teratogenic effects of antiepileptic drugs (AEDs). Pregnancy is known to affect the pharmacokinetics of older-generation AEDs. Understanding such alterations is important in the effort to optimise drug therapy since they may affect seizure control as well as fetal drug exposure. Therapeutic drug monitoring has therefore been recommended to control for changes in the disposition of the older-generation AEDs during pregnancy. Much less is known about gestation-induced alterations in the pharmacokinetics of the newer AEDs that have been introduced in the last 15 years. Lamotrigine is by far the most extensively studied of the newer AEDs. Pronounced alterations have been reported in the apparent clearance of lamotrigine, with an increase of >300% from baseline in late pregnancy in some patients on monotherapy, most likely due to enhanced metabolism. The available data suggest that the corresponding decline in plasma concentrations can be associated with loss of seizure control. More limited data indicate that a similar decline in plasma concentrations of the active monohydroxy derivative of oxcarbazepine may occur in late pregnancy. Preliminary experience also suggests that a significant fall in plasma concentrations of levetiracetam may occur during pregnancy. No systematic information is available on the pharmacokinetics during pregnancy of other newer AEDs (e.g. gabapentin, pregabalin, tiagabine, topiramate or zonisamide). Given the importance of maintaining optimal treatment of epilepsy during pregnancy, therapeutic drug monitoring appears to be justified for lamotrigine and oxcarbazepine in particular. Systematic studies of the effects of pregnancy on the pharmacokinetics of the other newer-generation AEDs are urgently needed.


  1. 1.
    Gaily E. Development and growth in children of epileptic mothers: a prospective controlled study [thesis]. Helsinki: University of Helsinki, 1990Google Scholar
  2. 2.
    Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol 2005 Nov; 4(11): 781–6PubMedCrossRefGoogle Scholar
  3. 3.
    Tomson T, Perucca E, Battino D. Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia 2004 Oct; 45(10): 1171–5PubMedCrossRefGoogle Scholar
  4. 4.
    Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004 Nov; 75(11): 1575–83PubMedCrossRefGoogle Scholar
  5. 5.
    Teramo K, Hiilesmaa V, Bardy A, et al. Fetal heart rate during a maternal grand mal epileptic seizure. J Perinat Med 1979; 7(1): 3–6PubMedCrossRefGoogle Scholar
  6. 6.
    Teramo K, Hiilesmaa V. Pregnancy and fetal complications in epileptic pregnancies. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 53–9Google Scholar
  7. 7.
    EURAP Study Group. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 2006 Feb 14; 66(3): 354–60CrossRefGoogle Scholar
  8. 8.
    Guidelines for the care of epileptic women of childbearing age. Commission on Genetics, Pregnancy, and the Child, International League Against Epilepsy. Epilepsia 1989 Jul–Aug; 30(4): 409–10CrossRefGoogle Scholar
  9. 9.
    Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology 1992 Apr; 42(4 Suppl. 5): 149–60PubMedGoogle Scholar
  10. 10.
    Yerby MS, Friel PN, McCormick K. Antiepileptic drug disposition during pregnancy. Neurology 1992 Apr; 42(4 Suppl. 5): 12–6PubMedGoogle Scholar
  11. 11.
    Guidelines for the care of women of childbearing age with epilepsy. Commission on Genetics, Pregnancy, and the Child, International League Against Epilepsy. Epilepsia 1993 Jul–Aug; 34(4): 588–9CrossRefGoogle Scholar
  12. 12.
    Committee on Educational Bulletins of the American College of Obstetricians and Gynecologists. Seizure disorders in pregnancy. ACOG educational bulletin number 231, December 1996. Int J Gynaecol Obstet 1997 Mar; 56(3): 279–86CrossRefGoogle Scholar
  13. 13.
    Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: management issues for women with epilepsy (summary statement). Epilepsia 1998 Nov; 39(11): 1226–31CrossRefGoogle Scholar
  14. 14.
    Crawford P, Appleton R, Betts T, et al. Best practice guidelines for the management of women with epilepsy. Seizure 1999 Jun; 8(4): 201–17PubMedCrossRefGoogle Scholar
  15. 15.
    Scottish Intercollegiate Guidelines Network. Diagnosis and management of epilepsy in adults: a national clinical guideline. Guideline number 70 [online]. Edinburgh: Royal College of Physicians, 2003. Available from URL: [Accessed 2007 Jan 8]
  16. 16.
    UK National Institute for Clinical Excellence. Newer drugs for epilepsy in adults: technology appraisal 76 [online]. London: National Institute for Clinical Excellence, 2004. Available from URL: [Accessed 2007 Jan 8]
  17. 17.
    Perucca E. Drug metabolism in pregnancy, infancy and childhood. Pharmacol Ther 1987; 34(1): 129–43PubMedCrossRefGoogle Scholar
  18. 18.
    Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 2003 Sep 1;61 (6 Suppl. 2): S35–42CrossRefGoogle Scholar
  19. 19.
    Commission on Genetics, Pregnancy, and the Child, International League Against Epilepsy. Guidelines for the care of epileptic women of childbearing age. Epilepsia 1989 Jul–Aug; 30(4): 409–10CrossRefGoogle Scholar
  20. 20.
    Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005; 44(10): 989–1008PubMedCrossRefGoogle Scholar
  21. 21.
    Perucca E, Crema A. Plasma protein binding of drugs in pregnancy. Clin Pharmacokinet 1982; 7(4): 336–52PubMedCrossRefGoogle Scholar
  22. 22.
    Yerby MS, Friel PN, McCormick K, et al. Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding. Epilepsy Res 1990 Apr; 5(3): 223–8PubMedCrossRefGoogle Scholar
  23. 23.
    Dansky L, Andermann E, Shervin A, et al. Plasma levels of pheytoin during pregnancy and the puerperium. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 155–62Google Scholar
  24. 24.
    Bardy AH, Hiilesmaa VK, Teramo KA. Serum phenytoin during pregnancy, labor and puerperium. Acta Neurol Scand 1987 Jun; 75(6): 374–5PubMedCrossRefGoogle Scholar
  25. 25.
    Battino D, Avanzini G, Bossi L, et al. Monitoring of antiepileptic drugs plasma levels during pregnancy and puerperium. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy and the child. New York: Raven Press, 1982: 147–54Google Scholar
  26. 26.
    Tomson T, Lindbom U, Ekqvist B, et al. Disposition of carbamazepine and phenytoin in pregnancy. Epilepsia 1994 Jan–Feb; 35(1): 131–5PubMedCrossRefGoogle Scholar
  27. 27.
    Tomson T, Lindbom U, Ekqvist B, et al. Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. Epilepsia 1994 Jan–Feb; 35(1): 122–30PubMedCrossRefGoogle Scholar
  28. 28.
    Battino D, Binelli S, Bossi L, et al. Plasma concentrations of carbamazepine and carbamazepine 10, 11-epoxide during pregnancy and after delivery. Clin Pharmacokinet 1985 May–Jun; 10(3): 279–84PubMedCrossRefGoogle Scholar
  29. 29.
    Yerby MS, Friel PN, Miller DQ. Carbamazepine protein binding and disposition in pregnancy. Ther Drug Monit 1985; 7(3): 269–73PubMedCrossRefGoogle Scholar
  30. 30.
    Bernus I, Hooper WD, Dickinson RG, et al. Metabolism of carbamazepine and co-administered anticonvulsants during pregnancy. Epilepsy Res 1995 May; 21(1): 65–75PubMedCrossRefGoogle Scholar
  31. 31.
    Battino D, Binelli S, Bossi L, et al. Changes in primidone/phenobarbitone ratio during pregnancy and the puerperium. Clin Pharmacokinet 1984 May–Jun; 9(3): 252–60PubMedCrossRefGoogle Scholar
  32. 32.
    Rating D, Nau H, Jager-Roman E, et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatr Scand 1982 Mar; 71(2): 301–11PubMedCrossRefGoogle Scholar
  33. 33.
    Omtzigt JG, Los FJ, Meijer JW, et al. The 10, 11-epoxide-10,11-diol pathway of carbamazepine in early pregnancy in maternal serum, urine, and amniotic fluid: effect of dose, comedication, and relation to outcome of pregnancy. Ther Drug Monit 1993 Feb; 15(1): 1–10PubMedCrossRefGoogle Scholar
  34. 34.
    Philbert A, Pedersen B, Dam M. Concentration of valproate during pregnancy, in the newborn and in breast milk. Acta Neurol Scand 1985 Nov; 72(5): 460–3PubMedCrossRefGoogle Scholar
  35. 35.
    Stewart BH, Kugler AR, Thompson PR, et al. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993 Feb; 10(2): 276–81PubMedCrossRefGoogle Scholar
  36. 36.
    McLean MJ. Gabapentin. Epilepsia 1995; 36 Suppl. 2: S73–86PubMedCrossRefGoogle Scholar
  37. 37.
    Vollmer KO, von Hodenberg A, Kölle EU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneim Forsch Drug Res 1988; 36: 830–9Google Scholar
  38. 38.
    Öhman I, Vitols S, Tomson T. Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy? Epilepsia 2005 Oct; 46(10): 1621–4PubMedCrossRefGoogle Scholar
  39. 39.
    Fitton A, Goa KL. Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs 1995 Oct; 50(4): 691–713PubMedCrossRefGoogle Scholar
  40. 40.
    Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997 May; 43(5): 457–65PubMedCrossRefGoogle Scholar
  41. 41.
    Tomson T, Ohman I, Vitols S. Lamotrigine in pregnancy and lactation: a case report. Epilepsia 1997 Sep; 38(9): 1039–41PubMedCrossRefGoogle Scholar
  42. 32.
    Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 2000 Jun; 41(6): 709–13PubMedCrossRefGoogle Scholar
  43. 43.
    Tran TA, Leppik IE, Blesi K, et al. Lamotrigine clearance during pregnancy. Neurology 2002 Jul 23; 59(2): 251–5PubMedCrossRefGoogle Scholar
  44. 44.
    Pennell PB, Newport DJ, Stowe ZN, et al. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 2004 Jan; 62(2): 292–5PubMedCrossRefGoogle Scholar
  45. 45.
    de Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004 Aug; 63(3): 571–3PubMedCrossRefGoogle Scholar
  46. 46.
    Petrenaite V, Sabers A, Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res 2005 Jul; 65(3): 185–8PubMedCrossRefGoogle Scholar
  47. 47.
    Pennell PB, Ritchie JC, Newport DJ, et al. Defining fetal exposure to lamotrigine [abstract]. Epilepsia 2004 Oct; 45 Suppl. 7: 233Google Scholar
  48. 48.
    Garnett WR. Lamotrigine: pharmacokinetics. J Child Neurol 1997 Nov; 12 Suppl. 1: S10–5PubMedCrossRefGoogle Scholar
  49. 49.
    Tomson T, Luef G, Sabers A, et al. Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology 2006; 37: 1297–9CrossRefGoogle Scholar
  50. 50.
    Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003 Jun; 2(6): 347–56PubMedCrossRefGoogle Scholar
  51. 51.
    Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000 Feb; 85(2): 77–85PubMedCrossRefGoogle Scholar
  52. 52.
    Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia 2001 Aug; 42 Suppl. 4: 24–7PubMedCrossRefGoogle Scholar
  53. 53.
    Johannessen SI, Heide G, Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. Epilepsia 2005 May; 46(5): 775–7PubMedCrossRefGoogle Scholar
  54. 54.
    Penneil PB, Roganti A, Helmers S, et al. The impact of pregnancy and childbirth on the elimination of levetiracetam [abstract]. Epilepsia 2005 Oct; 46 Suppl. 8: 89Google Scholar
  55. 55.
    May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 2003; 42(12): 1023–42PubMedCrossRefGoogle Scholar
  56. 56.
    Mazzucchelli I, Onat FY, Ozkara C, et al. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia 2006 Mar; 47(3): 504–9PubMedCrossRefGoogle Scholar
  57. 57.
    Langtry HD, Gillis JC, Davis R. Topiramate: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997 Nov; 54(5): 752–73PubMedCrossRefGoogle Scholar
  58. 58.
    Adin J, Gomez MC, Blanco Y, et al. Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications. Ther Drug Monit 2004 Jun; 26(3): 251–7PubMedCrossRefGoogle Scholar
  59. 59.
    Ohman I, Vitols S, Luef G, et al. Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. Epilepsia 2002 Oct; 43(10): 1157–60PubMedCrossRefGoogle Scholar
  60. 60.
    Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs: focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet 1996 Jul; 31(1): 29–46PubMedCrossRefGoogle Scholar
  61. 61.
    Seino M, Naruto S, Ito T, et al. Zonisamide. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs, 4th ed. New York: Raven Press, 1995: 1001–24Google Scholar
  62. 62.
    Kawada K, Itoh S, Kusaka T, et al. Pharmacokinetics of zonisamide in perinatal period. Brain Dev 2002 Mar; 24(2): 95–7PubMedCrossRefGoogle Scholar
  63. 63.
    Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004; 45 Suppl. 6: 13–8PubMedCrossRefGoogle Scholar
  64. 64.
    Adkins JC, Noble S. Tiagabine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 1998 Mar; 55(3): 437–60PubMedCrossRefGoogle Scholar
  65. 65.
    Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 2003 Jun; 25(3): 347–63PubMedCrossRefGoogle Scholar
  66. 66.
    Adab N. Birth defects and epilepsy medication. Expert Rev Neurother 2006 Jun; 6(6): 833–45PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Department of Clinical NeuroscienceKarolinska InstitutetStockholmSweden
  2. 2.National Neurological InstituteCarlo BestaMilanItaly
  3. 3.Department of NeurologyKarolinska University HospitalStockholmSweden

Personalised recommendations